Citation Report
List of articles citing

ASH and NASH

DOI: 10.1159/000323886
Digestive Diseases, 2011, 29, 202-10.

#	Paper	IF	Citations
64	ASH and NASH. *Digestive Diseases*, **2011**, 29, 202-10	3.2	59
63	Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. *Case Reports in Gastroenterology*, **2012**, 6, 538-44	1	25
62	Integration of cellular bioenergetics with mitochondrial quality control and autophagy. *Biological Chemistry*, **2012**, 393, 1485-1512	4.5	275
61	Medical Assessment and Preparation of Patients Undergoing Bariatric Surgery. **2012**,		
60	From NAFLD in clinical practice to answers from guidelines. *Journal of Hepatology*, **2013**, 59, 859-71	13.4	249
59	Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 392-400	6.1	126
58	Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. *Alcoholism: Clinical and Experimental Research*, **2013**, 37 Suppl 1, E247-52	3.7	31
57	Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. *Clinica Chimica Acta*, **2013**, 424, 99-103	6.2	216
56	Current concepts and management approaches in nonalcoholic fatty liver disease. *Scientific World Journal, The*, **2013**, 2013, 481893	2.2	50
55	Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. *World Journal of Gastroenterology*, **2014**, 20, 8377-92	5.6	53
54	Zeaxanthin dipalmitate therapeutically improves hepatic functions in an alcoholic fatty liver disease model through modulating MAPK pathway. *PLoS ONE*, **2014**, 9, e95214	3.7	36
53	Liver fibrosis markers in alcoholic liver disease. *World Journal of Gastroenterology*, **2014**, 20, 8018-23	5.6	33
52	Astaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene expression in diet-induced obesity mice. *British Journal of Nutrition*, **2014**, 112, 1797-804	3.6	46
51	Role of mitochondria in nonalcoholic fatty liver disease. *International Journal of Molecular Sciences*, **2014**, 15, 8713-42	6.3	183
50	Non-alcoholic fatty liver disease in patients with diabetes mellitus. *Expert Review of Endocrinology and Metabolism*, **2014**, 9, 503-514	4.1	
49	Alcohol activates the hedgehog pathway and induces related procarcinogenic processes in the alcohol-preferring rat model of hepatocarcinogenesis. *Alcoholism: Clinical and Experimental Research*, **2014**, 38, 787-800	3.7	25
48	New and Improved Imaging Modalities for NAFLD. *Current Hepatology Reports*, **2014**, 13, 88-96	1	1

47	A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. *Journal of the Academy of Nutrition and Dietetics* , **2014**, 114, 1181-94	3.9	60
46	The complement system in human cardiometabolic disease. *Molecular Immunology*, **2014**, 61, 135-48	4.3	76
45	Acides gras polyinsaturés oméga 3 et toxicité hépatique de l'éthanol : rôle du remodelage membranaire. *Nutrition Clinique Et Metabolisme*, **2014**, 28, 17-28	0.8	0
44	Non-alcoholic fatty liver disease among sasang constitutional types: a population-based study in Korea. *BMC Complementary and Alternative Medicine*, **2015**, 15, 399	4.7	7
43	. **2015**,		
42	General assessment and management. **2015**, 135-146		
41	Chronic alcohol consumption potentiates the development of diabetes through pancreatic β-cell dysfunction. *World Journal of Biological Chemistry*, **2015**, 6, 1-15	3.8	37
40	Non-Alcoholic Fatty Liver Disease in Patients with Diabetes Mellitus: A Clinician's Perspective. *International Journal of Digestive Diseases*, **2015**, 01,		2
39	A comparison of the cardiometabolic profile of black South Africans with suspected non-alcoholic fatty liver disease (NAFLD) and excessive alcohol use. *Alcohol*, **2015**, 49, 165-72	2.7	7
38	Suppression of silent information regulator 1 activity in noncancerous tissues of hepatocellular carcinoma: Possible association with non-B non-C hepatitis pathogenesis. *Cancer Science*, **2015**, 106, 542-9	6.9	4
37	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. *Digestive and Liver Disease*, **2015**, 47, 997-1006	3.3	279
36	Insulin resistance in development and progression of nonalcoholic fatty liver disease. *World Journal of Gastrointestinal Pathophysiology*, **2016**, 7, 211-7	3.2	52
35	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. *Medicine (United States)*, **2016**, 95, e3446	1.8	25
34	Total liver fat quantification using three-dimensional respiratory self-navigated MRI sequence. *Magnetic Resonance in Medicine*, **2016**, 76, 1400-1409	4.4	7
33	Are the guidelines (AASLD, IASL, EASL, and BSG) of help in the management of patients with NAFLD?. **2016**, 131-137		
32	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. *Journal of Gastroenterology*, **2016**, 51, 586-96	6.9	33
31	Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease. *Digestive Diseases*, **2017**, 35, 323-333	3.2	5
30	New Potential Biomarker Proteins for Alcoholic Liver Disease Identified by a Comparative Proteomics Approach. *Journal of Cellular Biochemistry*, **2017**, 118, 1189-1200	4.7	5

29	Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death. *Oxidative Medicine and Cellular Longevity*, **2017**, 2017, 1838679	6.7	15
28	Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins. *Experimental and Molecular Pathology*, **2018**, 104, 125-129	4.4	7
27	Epidemiology of Hepatic Steatosis at a Tertiary Care Center: An MRI-based Analysis. *Academic Radiology*, **2018**, 25, 317-327	4.3	2
26	The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	62
25	Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH). *Experimental and Molecular Pathology*, **2018**, 105, 144-149	4.4	11
24	Non-alcoholic Fatty Liver in the Pathogenesis of Diabetes. **2019**, 227-235		
23	Zeaxanthin Dipalmitate in the Treatment of Liver Disease. *Evidence-based Complementary and Alternative Medicine*, **2019**, 2019, 1475163	2.3	1
22	The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH). *Experimental and Molecular Pathology*, **2019**, 108, 156-163	4.4	1
21	Effect of Betaine Supplementation on Liver Tissue and Ultrastructural Changes in Methionine-Choline-Deficient Diet-Induced NAFLD. *Microscopy and Microanalysis*, **2020**, 26, 997-1006	0.5	3
20	Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. *Frontiers in Pharmacology*, **2020**, 11, 603926	5.6	38
19	[Histopathological diagnosis and differential diagnosis of nonalcoholic fatty liver disease]. *Der Pathologe*, **2020**, 41, 434-443	1	3
18	Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. *Cancers*, **2020**, 12,	6.6	16
17	Hepatocyte-Specific Expression of Human Carboxylesterase 1 Attenuates Diet-Induced Steatohepatitis and Hyperlipidemia in Mice. *Hepatology Communications*, **2020**, 4, 527-539	6	4
16	Fatty liver diseases, mechanisms, and potential therapeutic plant medicines. *Chinese Journal of Natural Medicines*, **2020**, 18, 161-168	2.8	2
15	Animal Evidence for Synergistic Induction of Hepatic Injury by Dietary Fat and Alcohol Consumption and Its Potential Mechanisms. *Journal of Personalized Medicine*, **2021**, 11,	3.6	0
14	Effects of Alcohol on Liver Apparent Diffusion Coefficient values: A Single Center Study. *Akademik Gastroenteroloji Dergisi*, 1-4		
13	Modeling alcohol-associated liver disease in a human Liver-Chip. *Cell Reports*, **2021**, 36, 109393	10.6	6
12	Modeling alcoholic liver disease in a human Liver-Chip.		2

11	Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. *Clinical and Molecular Hepatology*, **2020**, 26, 196-208	6.9	5
10	Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. *World Journal of Gastroenterology*, **2012**, 18, 5211-8	5.6	28
9	Pediatric fatty liver disease: role of ethnicity and genetics. *World Journal of Gastroenterology*, **2014**, 20, 7347-55	5.6	47
8	Epidemiology of fatty liver: an update. *World Journal of Gastroenterology*, **2014**, 20, 9050-4	5.6	59
7	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. *Gut and Liver*, **2016**, 10, 295-302	4.8	9
6	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. **2013**, 497-506		
5	The Antioxidant, Anti-inflammatory, and Antiapoptotic Effects of Wolfberry in Fatty Liver Disease. **2015**, 45-63		
4	Lebererkrankungen. **2016**, 319-349		
3	Measuring the burden--current and future research trends: results from the NIAAA Expert Panel on Alcohol and Chronic Disease Epidemiology. **2013**, 35, 250-9		6
2	Src kinase as a potential therapeutic target in non-alcoholic and alcoholic steatohepatitis. *Clinical and Translational Discovery*, **2022**, 2,		
1	Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH.. *Metabolites*, **2022**, 12,	5.6	1